Get the Stockscreener App
4.76
3.48%
0.16
After Hours:
4.76
Athira Pharma Inc stock is traded at $4.76, with a volume of 54,502.
It is up +3.48% in the last 24 hours and up +31.49% over the past month.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.
See More
Previous Close:
$4.60
Open:
$4.7051
24h Volume:
54,502
Relative Volume:
0.70
Market Cap:
$18.14M
Revenue:
-
Net Income/Loss:
$-117.67M
P/E Ratio:
-1.5405
EPS:
-3.09
Net Cash Flow:
$-101.06M
1W Performance:
+1.28%
1M Performance:
+31.49%
6M Performance:
+1,650%
1Y Performance:
+633.66%
1-Day Range:
$4.60
$4.95
1-Week Range:
$4.42
$5.00
52-Week Range:
$0.2195
$5.00
Athira Pharma Inc Stock (ATHA) Company Profile
Name
Athira Pharma Inc
Sector
Industry
Phone
(425) 620-8501
Address
18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL
Compare ATHA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATHA
Athira Pharma Inc
|
4.76 | 18.14M | 0 | -117.67M | -101.06M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.03 | 110.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
702.75 | 76.23B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.76 | 61.08B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
914.59 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
203.56 | 43.00B | 447.02M | -1.18B | -906.14M | -6.1812 |
Athira Pharma Inc Stock (ATHA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-19-24 | Downgrade | Mizuho | Outperform → Neutral |
| Sep-04-24 | Downgrade | BTIG Research | Buy → Neutral |
| Sep-04-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Sep-04-24 | Downgrade | Rodman & Renshaw | Buy → Neutral |
| Aug-19-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-17-22 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Jul-07-22 | Initiated | Mizuho | Buy |
| Jun-23-22 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-23-22 | Downgrade | Jefferies | Buy → Hold |
| Jun-23-22 | Downgrade | Stifel | Buy → Hold |
| May-10-22 | Initiated | BTIG Research | Buy |
| Apr-21-22 | Initiated | Berenberg | Buy |
| Dec-15-21 | Initiated | Goldman | Neutral |
| Oct-13-20 | Initiated | Goldman | Buy |
| Oct-13-20 | Initiated | JMP Securities | Mkt Outperform |
| Oct-13-20 | Initiated | Jefferies | Buy |
| Oct-13-20 | Initiated | Stifel | Buy |
View All
Athira Pharma Inc Stock (ATHA) Latest News
How Athira Pharma Inc. stock performs during Fed tightening cycles2025 Bull vs Bear & AI Powered Buy and Sell Recommendations - newser.com
Athira Pharma Inc. stock outlook for YEARGap Up & Weekly Market Pulse Updates - newser.com
Why Athira Pharma Inc. stock is popular among millennialsEarnings Trend Report & Daily Oversold Stock Bounce Ideas - newser.com
Why Athira Pharma Inc. stock could benefit from AI revolution2025 Market Overview & Free Accurate Trade Setup Notifications - newser.com
What makes Athira Pharma Inc. stock attractive to growth fundsJuly 2025 Breakouts & Long-Term Safe Investment Ideas - newser.com
Top chart patterns to watch in Athira Pharma Inc.July 2025 EndofMonth & Real-Time Volume Triggers - newser.com
What indicators show strength in Athira Pharma Inc.July 2025 Pullbacks & Capital Efficient Trade Techniques - newser.com
What analyst consensus says on Athira Pharma Inc. stock2025 Market Outlook & Capital Efficient Trade Techniques - newser.com
Will Athira Pharma Inc. continue its uptrendEarnings Growth Report & Real-Time Chart Breakout Alerts - newser.com
Update Recap: Is Athira Pharma Inc. stock ready for breakoutBull Run & Daily Chart Pattern Signal Reports - Fundação Cultural do Pará
How to escape a deep drawdown in Athira Pharma Inc.Dividend Hike & Low Risk Investment Opportunities - newser.com
Risk vs reward if holding onto Athira Pharma Inc.Quarterly Growth Report & Accurate Intraday Trading Signals - newser.com
Athira Pharma Inc. stock volume spike explainedWeekly Profit Report & Weekly Consistent Profit Watchlists - newser.com
Can Athira Pharma Inc. stock deliver consistent earnings growthDollar Strength & Long-Term Growth Portfolio Plans - newser.com
Will Athira Pharma Inc. stock benefit from AI adoptionWeekly Profit Analysis & Consistent Return Investment Signals - newser.com
Real time alert setup for Athira Pharma Inc. performanceRate Cut & Consistent Return Strategy Ideas - newser.com
Is Athira Pharma Inc. stock cheap at current valuationJuly 2025 Review & Weekly Stock Performance Updates - newser.com
Athira Pharma Cuts Losses And Sets Sights On ALS Trials - Finimize
Athira Pharma, Inc. (ATHA) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Athira Pharma Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Athira Pharma Reports Reduced Losses Amid Cost Cuts - TipRanks
Athira Pharma Inc Reports Q3 2025 EPS of -$1.68, Missing Estimat - GuruFocus
Athira Pharma Reports Third Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Athira Pharma Inc Stock (ATHA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.05%
0.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):